Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma

Authors: Xin Zheng, Shan Xing, Xiao-Min Liu, Wen Liu, Dan Liu, Pei-Dong Chi, Hao Chen, Shu-Qin Dai, Qian Zhong, Mu-Sheng Zeng, Wan-Li Liu

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Elevated serum YKL-40 levels have been observed in various cancers. We evaluated the diagnostic performance of serum YKL-40 alone or in combination with the CEA, CYFRA21-1 and SCCA tumor markers for patients with esophageal squamous cell carcinoma (ESCC).

Methods

YKL-40 was detected in ESCC cell lines and tissues by real-time RT-PCR, Western blotting and ELISA. YKL-40 protein expression was determined in 20 ESCC tumor tissues using immunohistochemistry. Serum YKL-40 was measured by ELISA in 126 healthy donors, 59 patients with benign esophageal diseases and 150 patients with ESCC. Serum CEA, CYFRA21-1 and SCCA were determined by electrochemiluminescence.

Results

YKL-40 mRNA and protein were observed in ESCC cancer cell lines, tissues and cell culture media, respectively. YKL-40 expression was observed in 17 of 20 ESCC samples (85%). Serum YKL-40 concentration was significantly elevated in patients with ESCC (Range: 6.95-502.10 ng/ml) compared with patients with benign diseases (Range: 1.21-429.30 ng/ml; P = 0.038) and healthy controls (Range: 2.56-132.26 ng/ml; P < 0.001). ROC curves demonstrated that serum YKL-40 has a sensitivity of 72.70%, a specificity of 84.13% and an AUC of 0.874 for the diagnosis of ESCC, which was superior to CEA (Sen: 8.00%; Spe: 96.80%, AUC = 0.652), CYFRA21-1 (Sen: 40.00%; Spe: 92.06%, AUC = 0.746) and SCCA (Sen: 32.67%; Spe: 94.44%, AUC = 0.789). The YKL-40 and SCCA combination was better for diagnosing ESCC (Sen: 82.00%, Spe: 79.37%, PPV: 82.55 and NPV: 78.74; AUC = 0.917) than the YKL-40 and CEA combination (Sen: 74.00%, Spe: 83.20%, PPV: 84.09 and NPV: 72.73; AUC = 0.877), the YKL-40 and CYFRA21-1 combination (Sen: 82.00%, Spe: 77.78%, PPV: 81.46% and NPV: 78.40%; AUC = 0.897) or the CEA, CYFRA21-1 and SCCA combination (Sen: 56.67%, Spe: 84.80%, PPV: 81.73 and NPV: 61.99; AUC = 0.831). Associations between serum YKL-40 levels and the clinic characteristics of ESCC were not significant, with the exception of age (p = 0.001).

Conclusions

ESCC tumor cells and tissues express YKL-40. Serum YKL-40 may be a potential biomarker for ESCC. Serum YKL-40 in combination with SCCA significantly increases the sensitivity of detecting ESCC.
Appendix
Available only for authorised users
Literature
2.
go back to reference Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001, 19: 305-313.PubMed Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001, 19: 305-313.PubMed
3.
go back to reference Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002, 359: 1727-1733.CrossRef Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002, 359: 1727-1733.CrossRef
4.
go back to reference Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007, 25: 1160-1168.CrossRefPubMed Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007, 25: 1160-1168.CrossRefPubMed
5.
go back to reference Hu Y, Zheng B, Rong TH, Fu JH, Zhu ZH, Yang H, Luo KJ, Li YF: Prognostic analysis of the patients with stage-III esophageal squamous cell carcinoma after radical esophagectomy. Chin J Cancer. 2010, 29: 178-183.CrossRefPubMed Hu Y, Zheng B, Rong TH, Fu JH, Zhu ZH, Yang H, Luo KJ, Li YF: Prognostic analysis of the patients with stage-III esophageal squamous cell carcinoma after radical esophagectomy. Chin J Cancer. 2010, 29: 178-183.CrossRefPubMed
6.
go back to reference Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, Watanabe M, Sugimachi K: CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer. 2000, 89: 1413-1417.CrossRefPubMed Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, Watanabe M, Sugimachi K: CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer. 2000, 89: 1413-1417.CrossRefPubMed
7.
go back to reference Mealy K, Feely J, Reid I, McSweeney J, Walsh T, Hennessy TP: Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol. 1996, 22: 505-507.CrossRefPubMed Mealy K, Feely J, Reid I, McSweeney J, Walsh T, Hennessy TP: Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol. 1996, 22: 505-507.CrossRefPubMed
8.
go back to reference Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T: CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer. 1997, 79: 1647-1655.CrossRefPubMed Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T: CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer. 1997, 79: 1647-1655.CrossRefPubMed
9.
go back to reference Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS, Liu WL: Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med. 2010, 8: 81-CrossRefPubMedPubMedCentral Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS, Liu WL: Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med. 2010, 8: 81-CrossRefPubMedPubMedCentral
10.
go back to reference Bleau G, Massicotte F, Merlen Y, Boisvert C: Mammalian chitinase-like proteins. EXS. 1999, 87: 211-221.PubMed Bleau G, Massicotte F, Merlen Y, Boisvert C: Mammalian chitinase-like proteins. EXS. 1999, 87: 211-221.PubMed
11.
go back to reference Johansen JS, Jensen HS, Price PA: A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol. 1993, 32: 949-955.CrossRefPubMed Johansen JS, Jensen HS, Price PA: A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol. 1993, 32: 949-955.CrossRefPubMed
12.
go back to reference Stawerski P, Wagrowska-Danilewicz M, Stasikowska-Kanicka O, Danilewicz M: Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers. Pathol Res Pract. 2011, 207: 573-576.CrossRefPubMed Stawerski P, Wagrowska-Danilewicz M, Stasikowska-Kanicka O, Danilewicz M: Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers. Pathol Res Pract. 2011, 207: 573-576.CrossRefPubMed
13.
go back to reference Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA: Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol Biomarkers Prev. 2006, 15: 194-202.CrossRefPubMed Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA: Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol Biomarkers Prev. 2006, 15: 194-202.CrossRefPubMed
14.
go back to reference Vind I, Johansen JS, Price PA, Munkholm P: Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003, 38: 599-605.CrossRefPubMed Vind I, Johansen JS, Price PA, Munkholm P: Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003, 38: 599-605.CrossRefPubMed
15.
go back to reference Zou L, He X, Zhang JW: The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz J Med Biol Res. 2010, 43 (12): 1232-1238.CrossRefPubMed Zou L, He X, Zhang JW: The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz J Med Biol Res. 2010, 43 (12): 1232-1238.CrossRefPubMed
16.
go back to reference Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W: Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011, 105: 1203-1209.CrossRefPubMedPubMedCentral Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W: Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011, 105: 1203-1209.CrossRefPubMedPubMedCentral
17.
go back to reference Thom I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E: Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010, 116: 4114-4121.CrossRefPubMed Thom I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E: Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010, 116: 4114-4121.CrossRefPubMed
18.
go back to reference Zhu CB, Chen LL, Tian JJ, Su L, Wang C, Gai ZT, Du WJ, Ma GL: Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann Surg Oncol. 2012, 19: 817-825.CrossRefPubMed Zhu CB, Chen LL, Tian JJ, Su L, Wang C, Gai ZT, Du WJ, Ma GL: Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann Surg Oncol. 2012, 19: 817-825.CrossRefPubMed
19.
go back to reference Horbinski C, Wang G, Wiley CA: YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol. 2010, 3: 226-237.PubMedPubMedCentral Horbinski C, Wang G, Wiley CA: YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol. 2010, 3: 226-237.PubMedPubMedCentral
20.
go back to reference Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J: Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007, 104: 435-442.CrossRefPubMed Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J: Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007, 104: 435-442.CrossRefPubMed
21.
go back to reference Hogdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Høgdall CK: High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep. 2003, 10: 1535-1538.PubMed Hogdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Høgdall CK: High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep. 2003, 10: 1535-1538.PubMed
22.
go back to reference Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brünner N, Harris AL: High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat. 2003, 80: 15-21.CrossRefPubMed Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brünner N, Harris AL: High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat. 2003, 80: 15-21.CrossRefPubMed
23.
go back to reference Choi IK, Kim YH, Kim JS, Seo JH: High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Acta Oncol. 2010, 49: 861-864.CrossRefPubMed Choi IK, Kim YH, Kim JS, Seo JH: High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Acta Oncol. 2010, 49: 861-864.CrossRefPubMed
24.
go back to reference Xu CH, Yu LK, Hao KK: Serum YKL-40 Level Is Associated with the Chemotherapy Response and Prognosis of Patients with Small Cell Lung Cancer. PLoS One. 2014, 9 (5): e96384-CrossRefPubMedPubMedCentral Xu CH, Yu LK, Hao KK: Serum YKL-40 Level Is Associated with the Chemotherapy Response and Prognosis of Patients with Small Cell Lung Cancer. PLoS One. 2014, 9 (5): e96384-CrossRefPubMedPubMedCentral
25.
go back to reference Zhang H, Jin Y, Chen X, Jin C, Law S, Tsao SW, Kwong YL: Cytogenetic aberrations in immortalization of esophageal epithelial cells. Cancer Genet Cytogenet. 2006, 165: 25-35.CrossRefPubMed Zhang H, Jin Y, Chen X, Jin C, Law S, Tsao SW, Kwong YL: Cytogenetic aberrations in immortalization of esophageal epithelial cells. Cancer Genet Cytogenet. 2006, 165: 25-35.CrossRefPubMed
26.
go back to reference Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS: Prognostic relevance of Centromere protein H expression in esophageal carcinoma. BMC Cancer. 2008, 8: 233-CrossRefPubMedPubMedCentral Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS: Prognostic relevance of Centromere protein H expression in esophageal carcinoma. BMC Cancer. 2008, 8: 233-CrossRefPubMedPubMedCentral
27.
go back to reference Yang GF, Cai PY, Li XM, Deng HX, He WP, Xie D: Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Ai Zheng. 2009, 28: 142-145.PubMed Yang GF, Cai PY, Li XM, Deng HX, He WP, Xie D: Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Ai Zheng. 2009, 28: 142-145.PubMed
28.
go back to reference Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH: YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol. 2013, 35: 277-286.CrossRefPubMed Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH: YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol. 2013, 35: 277-286.CrossRefPubMed
29.
go back to reference Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL, Zhan WH, Wen JM, Guan XY: Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009, 40: 1790-1797.CrossRefPubMed Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL, Zhan WH, Wen JM, Guan XY: Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009, 40: 1790-1797.CrossRefPubMed
30.
go back to reference Hogdall EV, Ringsholt M, Hogdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Moller L, Price PA, Christensen LH: YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer. 2009, 9: 8-CrossRefPubMedPubMedCentral Hogdall EV, Ringsholt M, Hogdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Moller L, Price PA, Christensen LH: YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer. 2009, 9: 8-CrossRefPubMedPubMedCentral
31.
go back to reference Radojicic J, Zaravinos A, Spandidos DA: HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. Int J Biol Markers. 2012, 27: 1-12.CrossRefPubMed Radojicic J, Zaravinos A, Spandidos DA: HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. Int J Biol Markers. 2012, 27: 1-12.CrossRefPubMed
32.
go back to reference Putz A, Hartmann AA, Fontes PR, Alexandre CO, Silveira DA, Klug SJ, Rabes HM: TP53 mutation pattern of esophageal squamous cell carcinomas in a high risk area (Southern Brazil): role of life style factors. Int J Cancer. 2002, 98: 99-105.CrossRefPubMed Putz A, Hartmann AA, Fontes PR, Alexandre CO, Silveira DA, Klug SJ, Rabes HM: TP53 mutation pattern of esophageal squamous cell carcinomas in a high risk area (Southern Brazil): role of life style factors. Int J Cancer. 2002, 98: 99-105.CrossRefPubMed
33.
go back to reference Taccioli C, Chen H, Jiang Y, Liu XP, Huang K, Smalley KJ, Farber JL, Croce CM, Fong LY: Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature. Oncogene. 2012, 31: 4550-4558.CrossRefPubMed Taccioli C, Chen H, Jiang Y, Liu XP, Huang K, Smalley KJ, Farber JL, Croce CM, Fong LY: Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature. Oncogene. 2012, 31: 4550-4558.CrossRefPubMed
34.
go back to reference Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathe EA, Li P, Cai H, Yu L, Liu F, Hang D, Yang H, Wang XW, Ke Y, Harris CC: microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer. 2013, 132: 2901-2909.CrossRefPubMed Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathe EA, Li P, Cai H, Yu L, Liu F, Hang D, Yang H, Wang XW, Ke Y, Harris CC: microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer. 2013, 132: 2901-2909.CrossRefPubMed
35.
go back to reference Zhou MQ, Du Y, Liu YW, Wang YZ, He YQ, Yang CX, Wang WJ, Gao F: Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer. BMC Cancer. 2013, 13: 359-CrossRefPubMedPubMedCentral Zhou MQ, Du Y, Liu YW, Wang YZ, He YQ, Yang CX, Wang WJ, Gao F: Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer. BMC Cancer. 2013, 13: 359-CrossRefPubMedPubMedCentral
36.
go back to reference Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, Cao S, Hong M: Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer. 2012, 131: 406-416.CrossRefPubMed Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, Cao S, Hong M: Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer. 2012, 131: 406-416.CrossRefPubMed
37.
go back to reference Munck-Wikland E, Kuylenstierna R, Wahren B, Lindholm J, Haglund S: Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer. 1988, 62: 2281-2286.CrossRefPubMed Munck-Wikland E, Kuylenstierna R, Wahren B, Lindholm J, Haglund S: Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer. 1988, 62: 2281-2286.CrossRefPubMed
Metadata
Title
Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma
Authors
Xin Zheng
Shan Xing
Xiao-Min Liu
Wen Liu
Dan Liu
Pei-Dong Chi
Hao Chen
Shu-Qin Dai
Qian Zhong
Mu-Sheng Zeng
Wan-Li Liu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-490

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Reviewer acknowledgement

Reviewer acknowledgement 2013

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine